Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Heart failure-related quality-of-life impairment after myocardial infarction

P. Wohlfahrt, D. Jenča, J. Stehlik, V. Melenovský, J. Mrázková, V. Staněk, J. Kettner, M. Šramko, M. Želízko, V. Adámková, J. Piťha, J. Kautzner

. 2023 ; 112 (1) : 39-48. [pub] 20220318

Language English Country Germany

Document type Journal Article

AIMS: Recent advances in therapy led to a significant decrease in mortality and morbidity after myocardial infarction (MI). However, little is known about quality of life (QoL) after MI. We examined heart failure (HF)-related quality-of-life (QoL) impairment, its trajectories, and determinants after MI. METHODS: Data from a single-center prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were utilized. At 1 month and 1 year after hospital discharge, patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). RESULTS: In total, 850 patients (aged 65 ± 12 years, 27% female) hospitalized between June 2017 and October 2020 completed KCCQ at 1 month after discharge. Of these, 38.7% showed HF-related QoL impairment (KCCQ ≤ 75). In addition to characteristics of MI (MI size, diuretics need, heart rate), comorbidities as renal dysfunction and anemia were associated with QoL impairment. Of the 673 eligible, 500 patients (74.3%) completed KCCQ at 1 year after MI. On average, QoL improved by 5.9 ± 16.8 points during the first year after MI (p < 0.001); but, in 18% of patients QoL worsened. Diabetes control and hemoglobin level at the time of hospitalization were associated with QoL worsening. CONCLUSION: Two out of 5 patients after MI present with HF-related QoL impairment. In addition to guideline-directed MI management, careful attention to key non-cardiac comorbidities as chronic kidney disease, anemia and diabetes may lead to further augmentation of the benefit of modern therapies in terms of QoL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004845
003      
CZ-PrNML
005      
20230425171744.0
007      
ta
008      
230418s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00392-022-02008-z $2 doi
035    __
$a (PubMed)35304902
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Wohlfahrt, Peter $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. wohlfp@gmail.com $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Videnska 800, 140 59, Prague, Czech Republic. wohlfp@gmail.com $1 https://orcid.org/000000032390526X
245    10
$a Heart failure-related quality-of-life impairment after myocardial infarction / $c P. Wohlfahrt, D. Jenča, J. Stehlik, V. Melenovský, J. Mrázková, V. Staněk, J. Kettner, M. Šramko, M. Želízko, V. Adámková, J. Piťha, J. Kautzner
520    9_
$a AIMS: Recent advances in therapy led to a significant decrease in mortality and morbidity after myocardial infarction (MI). However, little is known about quality of life (QoL) after MI. We examined heart failure (HF)-related quality-of-life (QoL) impairment, its trajectories, and determinants after MI. METHODS: Data from a single-center prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were utilized. At 1 month and 1 year after hospital discharge, patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). RESULTS: In total, 850 patients (aged 65 ± 12 years, 27% female) hospitalized between June 2017 and October 2020 completed KCCQ at 1 month after discharge. Of these, 38.7% showed HF-related QoL impairment (KCCQ ≤ 75). In addition to characteristics of MI (MI size, diuretics need, heart rate), comorbidities as renal dysfunction and anemia were associated with QoL impairment. Of the 673 eligible, 500 patients (74.3%) completed KCCQ at 1 year after MI. On average, QoL improved by 5.9 ± 16.8 points during the first year after MI (p < 0.001); but, in 18% of patients QoL worsened. Diabetes control and hemoglobin level at the time of hospitalization were associated with QoL worsening. CONCLUSION: Two out of 5 patients after MI present with HF-related QoL impairment. In addition to guideline-directed MI management, careful attention to key non-cardiac comorbidities as chronic kidney disease, anemia and diabetes may lead to further augmentation of the benefit of modern therapies in terms of QoL.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a kvalita života $7 D011788
650    12
$a srdeční selhání $x epidemiologie $x terapie $7 D006333
650    _2
$a hospitalizace $7 D006760
650    12
$a infarkt myokardu $x komplikace $x epidemiologie $x terapie $7 D009203
650    12
$a anemie $7 D000740
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jenča, Dominik $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Stehlik, Josef $u University of Utah School of Medicine, Salt Lake City, UT, USA
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Mrázková, Jolana $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Staněk, Vladimír $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kettner, Jiří $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Šramko, Marek $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Želízko, Michael $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Adámková, Věra $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Piťha, Jan $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
773    0_
$w MED00155366 $t Clinical research in cardiology : official journal of the German Cardiac Society $x 1861-0692 $g Roč. 112, č. 1 (2023), s. 39-48
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35304902 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171741 $b ABA008
999    __
$a ok $b bmc $g 1925126 $s 1191054
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 112 $c 1 $d 39-48 $e 20220318 $i 1861-0692 $m Clinical research in cardiology $n Clin Res Cardiol $x MED00155366
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...